Franklin Resources Inc. Has $1.11 Million Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Franklin Resources Inc. raised its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTXFree Report) by 87.6% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 64,926 shares of the biopharmaceutical company’s stock after purchasing an additional 30,322 shares during the quarter. Franklin Resources Inc.’s holdings in TG Therapeutics were worth $1,109,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in TGTX. Corient Private Wealth LLC boosted its stake in shares of TG Therapeutics by 231.6% in the 4th quarter. Corient Private Wealth LLC now owns 93,381 shares of the biopharmaceutical company’s stock valued at $1,595,000 after purchasing an additional 65,220 shares during the last quarter. UBS Group AG boosted its position in TG Therapeutics by 67.2% during the fourth quarter. UBS Group AG now owns 564,836 shares of the biopharmaceutical company’s stock valued at $9,647,000 after acquiring an additional 226,971 shares during the last quarter. Norges Bank acquired a new stake in TG Therapeutics during the 4th quarter worth about $18,362,000. Private Portfolio Partners LLC bought a new position in shares of TG Therapeutics in the 4th quarter worth about $201,000. Finally, NBC Securities Inc. lifted its stake in shares of TG Therapeutics by 34.5% in the 4th quarter. NBC Securities Inc. now owns 9,401 shares of the biopharmaceutical company’s stock valued at $160,000 after purchasing an additional 2,409 shares during the period. Institutional investors own 58.58% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. StockNews.com downgraded TG Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 24th. LADENBURG THALM/SH SH lifted their price objective on shares of TG Therapeutics from $39.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, May 2nd. The Goldman Sachs Group increased their target price on shares of TG Therapeutics from $12.00 to $13.00 and gave the stock a “neutral” rating in a research note on Thursday, February 29th. JPMorgan Chase & Co. restated an “overweight” rating and issued a $25.00 target price on shares of TG Therapeutics in a research note on Thursday, April 18th. Finally, HC Wainwright increased their price target on TG Therapeutics from $45.00 to $49.00 and gave the stock a “buy” rating in a report on Thursday, May 2nd. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $29.83.

Check Out Our Latest Stock Analysis on TG Therapeutics

Insider Transactions at TG Therapeutics

In related news, Director Laurence N. Charney sold 22,000 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $15.97, for a total transaction of $351,340.00. Following the transaction, the director now directly owns 215,229 shares of the company’s stock, valued at $3,437,207.13. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 9.20% of the company’s stock.

TG Therapeutics Price Performance

TGTX stock opened at $16.53 on Thursday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.84 and a current ratio of 3.62. The business has a 50-day simple moving average of $15.57 and a two-hundred day simple moving average of $15.70. The company has a market capitalization of $2.55 billion, a P/E ratio of 71.87 and a beta of 2.30. TG Therapeutics, Inc. has a 52-week low of $6.46 and a 52-week high of $29.32.

TG Therapeutics (NASDAQ:TGTXGet Free Report) last announced its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The company had revenue of $63.47 million for the quarter, compared to analysts’ expectations of $54.60 million. TG Therapeutics had a net margin of 14.24% and a return on equity of 31.34%. The firm’s quarterly revenue was up 713.5% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.28) EPS. Research analysts expect that TG Therapeutics, Inc. will post -0.01 EPS for the current fiscal year.

TG Therapeutics Profile

(Free Report)

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

Recommended Stories

Institutional Ownership by Quarter for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.